Optibiotix's probiotic strain launched in Italy by ALFASIGMA
The Italian pharmaceutical company will market this ‘first of its kind’ nutraceutical probiotic in Italy to address cholesterol reduction, the statement said.
ALFASIGMA, which saw 2018 revenues in excess of €1 billion, holds 3000 employees globally and is present in more than 90 countries through distributors and subsidiaries.
“We are pleased to communicate the launch of a new product developed by one of the largest pharmaceutical companies in Italy and containing our cholesterol reducing probiotic, LPLDL®,” said Stephen Prescott, Chief Executive of ProBiotix Health.
ProBiotix said the launch was being supported by an ‘extensive’ marketing campaign aimed at GPs, cardiologists, and pharmacists, to promote treatment for at risk patients using a scientifically formulated food supplement.
Optibiotix entered into an agreement with ALFASIGMA in June 2018 to exclusively commercialise food supplements containing OptiBiotix's LPLDL® strain in Italy.
In 2017, Italy’s probiotic supplements market was reportedly worth an estimated $500 million with growth forecasted at 25% per annum to 2021.
This makes Italy the largest and fastest growing probiotic market in Europe, and the second largest market in the world, the company emphasised.
Prescott acknowledged the product launch as another step in establishing LPLDL® as a global probiotic brand whilst also building ProBiotix into a profitable business in 2020.
Follow News & Updates from Optibiotix Health here:
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.